Skip to content

H.R. 383 · 118th Congress (2023–2025)

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)

The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.

In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers.

The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 383’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Diana Harshbarger (R-TN-1)
Cosponsors
26 cosponsors

13 original · 13 later

26 R

  1. Rep. Jim Banks (R-IN-3)· Original · Jan 17, 2023
  2. Rep. James R. Baird (R-IN-4)· Original · Jan 17, 2023
  3. Rep. Earl L. "Buddy" Carter (R-GA-1)· Original · Jan 17, 2023
  4. Rep. Jeff Duncan (R-SC-3)· Original · Jan 17, 2023
  5. Rep. Randy Feenstra (R-IA-4)· Original · Jan 17, 2023
  6. Rep. Paul A. Gosar (R-AZ-9)· Original · Jan 17, 2023
  7. Rep. Kevin Hern (R-OK-1)· Original · Jan 17, 2023
  8. Rep. Ronny Jackson (R-TX-13)· Original · Jan 17, 2023
  9. Rep. Doug Lamborn (R-CO-5)· Original · Jan 17, 2023
  10. Rep. Mary E. Miller (R-IL-15)· Original · Jan 17, 2023
  11. Rep. Christopher H. Smith (R-NJ-4)· Original · Jan 17, 2023
  12. Rep. Daniel Webster (R-FL-11)· Original · Jan 17, 2023
  13. Rep. Randy K. Weber, Sr. (R-TX-14)· Original · Jan 17, 2023
  14. Rep. Lauren Boebert (R-CO-3)· Later · Jan 24, 2023
  15. Rep. Mike Flood (R-NE-1)· Later · Jan 24, 2023
  16. Rep. Glenn Grothman (R-WI-6)· Later · Jan 24, 2023
  17. Rep. John R. Moolenaar (R-MI-2)· Later · Jan 24, 2023
  18. Rep. Pete Sessions (R-TX-17)· Later · Jan 24, 2023
  19. Rep. Mike Bost (R-IL-12)· Later · Jan 26, 2023
  20. Rep. Tony Gonzales (R-TX-23)· Later · Jan 26, 2023
  21. Rep. Brian J. Mast (R-FL-21)· Later · Jan 26, 2023
  22. Rep. Rudy Yakym III (R-IN-2)· Later · Jan 26, 2023
  23. Rep. Michael Guest (R-MS-3)· Later · Feb 6, 2023
  24. Rep. Anna Paulina Luna (R-FL-13)· Later · Mar 8, 2023
  25. Rep. Clay Higgins (R-LA-3)· Later · Mar 17, 2023
  26. Rep. Robert B. Aderholt (R-AL-4)· Later · Aug 11, 2023
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Jan 17, 2023 – Jan 27, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Jan 17, 2023
  2. HouseHealthReferred Jan 27, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (1)
  1. To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

    Display title, Official title · Introduced in House